- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04785638
An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries
An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, Phase 3, open-label, safety, tolerability, and characterization of pharmacokinetics study of the INL-001 (bupivacaine HCl) implant, at 300 mg, in patients following various soft-tissue surgeries: open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty. After a screening period, eligible patients will undergo study surgery under general anesthesia and have INL-001 implanted intraoperatively. Efficacy is also an exploratory measure in this study.
The study includes a screening period, an inpatient period (preoperative, intraoperative, postoperative) of approximately 5 days, and an outpatient follow-up period (up to 30 days after treatment). Posttreatment safety and/or efficacy assessments will be made throughout the study and as specifically scheduled through 96 hours posttreatment, on day 7 (telephone), on day 15 (clinic visit), and on day 30 (clinic visit). Unless the investigator determines further hospitalization is necessary, patients will be discharged approximately 96 hours posttreatment (inpatient day 5).
During the screening period, all patients will undergo eligibility and other screening and safety assessments. In addition, the investigator will administer the Pain Catastrophizing Scale (screening only) as an exploratory measure and the 15-item Quality of Recovery (QoR-15) questionnaire (baseline).
Adverse event and concomitant medication information, including use of rescue pain medication, will be collected throughout the study (inpatient and outpatient). Surgical wound healing/grading assessments and assessment for signs and symptoms potentially indicative of systemic bupivacaine toxicity will be made.
Blood samples for pharmacokinetic assessments will be collected from patients at multiple time points for the measurement of concentrations of bupivacaine in plasma.
After surgery, patient reports of pain intensity using an 11-point numeric pain rating scale (NPRS) will be recorded at multiple time points through 96 hours posttreatment. Patients will be permitted rescue medication (oral and/or intravenous) to manage breakthrough pain when it occurs. The QoR-15 questionnaire and Patient Global Assessment (for pain control) will be administered on an inpatient basis and on day 7. The Opioid Related Symptom Distress Scale will be administered on an inpatient basis.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Head of Clinical Operations
- Phone Number: 484-406-5214
- Email: rsmall@innocoll.com
Study Contact Backup
- Name: Head of Clinical Research, MD
- Phone Number: 484-406-5205
- Email: nskuban@innocoll.com
Study Locations
-
-
Alabama
-
Florence, Alabama, United States, 35630
- North Alabama Medical Center
-
Sheffield, Alabama, United States, 35660
- Helen Keller Hospital
-
-
California
-
Pasadena, California, United States, 91105
- Lotus Clinical Research
-
-
Ohio
-
Dayton, Ohio, United States, 45417
- Midwest Clinical Research
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
Houston, Texas, United States, 77004
- Daneshvari Solanki
-
Houston, Texas, United States, 77089
- Memorial Hermann
-
San Antonio, Texas, United States, 78229
- Endeavor Clinical Trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has a body mass index of 18-35 kg/m2.
- Has a planned (nonemergency) open ventral hernia repair, abdominoplasty (with rectus sheath plication, in the opinion of the surgeon), open abdominal hysterectomy, laparoscopic-assisted colectomy, or reduction mammoplasty to be conducted using standard surgical technique under general anesthesia.
- Has the ability and willingness to comply with all study procedures including being domiciled for at least 96 hours after surgery.
- Is willing to use opioid analgesia, if needed.
Exclusion Criteria:
- Has a known hypersensitivity to amide-type local anesthetics, fentanyl, morphine, oxycodone, acetaminophen, NSAIDs, or bovine products.
- Is scheduled for other significant concurrent surgical procedures (eg, cholecystectomy or additional cosmetic procedures concurrent with abdominoplasty).
- Has used an opioid analgesic on an extended daily basis (≥5 mg oral morphine equivalents per day for 3 or more days a week) within 4 weeks before surgery and/or chronically uses pain medication.
- Has any chronic painful condition (eg, fibromyalgia), as determined by the investigator, that may confound the assessment of pain associated with the study surgery.
- For open hernia repair, has open ventral hernia with primary suture repair and mesh placement requiring an incisional length greater than 12 cm.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: INL-001 (bupivacaine hydrochloride) implant
|
INL-001 (bupivacaine hydrochloride) implant
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the safety and tolerability
Time Frame: Day 1 through Day 30
|
The primary objective of the study is to evaluate the safety and tolerability of the INL-001 implant in patients.
Measured by frequency and incidents of adverse events.
|
Day 1 through Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Maximum (peak) plasma concentration
|
0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Tmax
Time Frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Time to maximum (peak) plasma concentration
|
0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Tlag
Time Frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Lag-time
|
0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
t½ Terminal Half life
Time Frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Terminal Half life
|
0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
λz
Time Frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Terminal phase rate constant
|
0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
AUC
Time Frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Area under the plasma concentration-time curve from Time 0 to last time of last quantifiable plasma concentration (AUC0-last)
|
0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
AUC0-∞
Time Frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
AUC from Time 0 to infinity
|
0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48, 72 and 96 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SPI24
Time Frame: 0 to 24 hours
|
Time-weighted sum of pain intensity from Time 0 through 24 hours (SPI24).
Lower score has a better outcome.
Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible".
Minimum value would be "0" and Maximum value would be 240.
Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours).
This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.
|
0 to 24 hours
|
SPI48
Time Frame: 0 to 48 hours
|
Time-weighted sum of pain intensity from Time 0 through 48 hours (SPI48).
Lower score has a better outcome.
Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible".
Minimum value would be "0" and Maximum value would be 480.
Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI48 = ∑[PI x (time t - time t-1)], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours).
This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.
|
0 to 48 hours
|
SPI72
Time Frame: 0 to 72 Hours
|
Time-weighted sum of pain intensity from Time 0 through 72 hours (SPI72) A lower score is a better outcome.
Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible" Minimum value would be "0" and Maximum value would be 720.
Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑[PI x (time t - time t-1)], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours).
This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.
|
0 to 72 Hours
|
Total use of opioid rescue analgesia
Time Frame: 0 to 24 hours postoperatively
|
Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome
|
0 to 24 hours postoperatively
|
Total use of opioid rescue analgesia
Time Frame: 0 to 72 hours postoperatively
|
Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome
|
0 to 72 hours postoperatively
|
Total use of opioid rescue analgesia
Time Frame: 0 to 48 hours postoperatively
|
Total use of opioid rescue analgesia (mg equivalent) -higher score means more analgesia was needed and worse outcome
|
0 to 48 hours postoperatively
|
Time to discharge from the postanesthesia care unit (PACU)
Time Frame: Immediately after the intervention/procedure/surgery
|
Time to discharge from the PACU
|
Immediately after the intervention/procedure/surgery
|
Opioid-related Symptom Distress Scale (OR-SDS)
Time Frame: 24, 48, 72, and 96 hours posttreatment
|
The OR-SDS is a measurement tool to assess patient experience following opioid use in the postoperative setting.
|
24, 48, 72, and 96 hours posttreatment
|
15-item Quality of Recovery (QoR-15) Questionnaire
Time Frame: 24, 48, 72, and 96 hours, and day 7 posttreatment
|
The 15-item Quality of Recovery (QoR-15) Questionnaire s a surgical recovery assessment tool.
The QoR-15 assesses postsurgical recovery from the patient's perspective and incorporates all 5 dimensions of health patient support, comfort, emotions, physical independence, and pain.
Investigator judgement will be used to determine if a positive finding on the QoR-15 is clinically significant and reportable as an adverse event.
|
24, 48, 72, and 96 hours, and day 7 posttreatment
|
Patient Global Assessment (PGA) as Related to Postoperative Pain
Time Frame: 24, 48, 72, and 96 hours, and day 7 posttreatment
|
The PGA will be administered by study staff who ask patients to rate "how well your pain has been controlled during the study" on a 5 point nominal scale: 0-poor, 1-fair, 2-good, 3-ery good, or 4-excellent.
|
24, 48, 72, and 96 hours, and day 7 posttreatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pathological Conditions, Anatomical
- Hernia, Abdominal
- Pain, Postoperative
- Hernia
- Hernia, Ventral
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Anesthetics, Local
- Bupivacaine
Other Study ID Numbers
- INN-CB-025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Postoperative
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
-
VA Office of Research and DevelopmentRecruitingTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty (Postoperative Pain)United States
-
VA Office of Research and DevelopmentCompletedTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty(Postoperative Pain)United States
Clinical Trials on INL-001 (bupivacaine hydrochloride) implant
-
InnocollMedpace, Inc.Completed
-
Perfuse Therapeutics, Inc.Recruiting
-
Perfuse Therapeutics, Inc.Recruiting
-
InnocollCompletedPain, Postoperative | AbdominoplastyUnited States
-
InnocollPremier Research Group plcCompletedPain, PostoperativeUnited States
-
InnocollPremier Research Group plcCompletedPostoperative Pain | Inguinal Hernia | HerniorrhaphyUnited States
-
InnocollCompletedPain, PostoperativeUnited States
-
Ain Shams UniversityRecruitingAnlgesia for Hip Arthroscopy by Assessing Quality of Different Type of Regional Block, Femoral Nerve Block Versus Fascia Iliaca BlockEgypt
-
InnocollPremier Research Group plcCompletedPostoperative Pain | HerniaUnited States
-
InnocollPremier Research Group plcCompletedHernioplastyUnited States